Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (October 19th Preview)
-
Merck KGaA expands RNAi pipeline with Silence Therapeutics buyout
Merck KGaA agreed to buy UK-based Silence Therapeutics for $1.3 billion to gain control of its siRNA program for rare disease. The deal targets divesiran, which delivered positive Phase 2 results in polycythemia vera, and is positioned as a specialized, genetic-medicine platform expansion for Merck KGaA. Under the terms reported, Merck KGaA will pay $20 in cash per Silence share, representing a 130% premium, with plans to close in the first quarter of 2027. Silence’s investors representing a minority block (14% of voting power) already agreed to the transaction, according to the deal terms. Analysts cited in the report said the Phase 2 efficacy profile could raise competitive expectations in polycythemia vera, where current standards include Jakafi and Takeda’s Mimrylo in development. Merck KGaA will need to advance divesiran through Phase 3 as it looks to differentiate in a crowded rare-hematology landscape. The transaction underscores how large pharma is continuing to build capabilities in RNA medicine, using acquisition to accelerate pipeline access rather than relying solely on internal discovery timelines.
-
China’s moves to restrict foreign biotech acquisitions
China has moved to restrict foreign acquisitions of biotech companies, tightening the rules for cross-border ownership in a sector that has increasingly attracted strategic interest from international players. The development is part of a broader effort to bring biotechnology investment and control under more direct national oversight. For global drugmakers and investors, the shift can change deal timelines, reduce optionality on regulatory approvals, and add new diligence requirements around governance, technology transfer, and data-handling commitments. The policy direction will be closely watched by both acquirers and targets as it affects the near-term feasibility of transactions involving platform technology, clinical-stage assets, and domestic supply chains. Market participants are expected to recalibrate deal structures and consider more joint-venture or licensing pathways where equity transfers face increased friction.
-
Oral immunotherapy in ulcerative colitis heats up as Gilead reports Phase 2 win
Gilead reported mid-stage results for emvistegrast, an oral therapy for ulcerative colitis, showing symptom elimination in a Phase 2 dose-finding trial. The company said a 200 mg daily regimen for 12 weeks produced a 23% placebo-adjusted clinical remission rate. The reported efficacy outperformed analyst expectations and is being framed by Gilead as a potential best-in-class oral option in a space where multiple mechanisms are competing to improve durable remission. The trial data were shared ahead of further development steps that will determine whether the program can translate into late-stage success. The readout adds to competitive pressure in oral inflammatory bowel disease (IBD) drug development, where endpoints, durability, and patient subgroups often determine differentiation in later trials. Gilead’s next phase of work will likely focus on confirming the remission signal across broader patient populations and aligning the safety profile with the dosing intensity required for maintenance goals.
-
Single-dose antibody clears SIV reservoirs in infant macaques
A single dose of a CCR5/CD3 bispecific antibody depleted the SIV reservoir in infant macaques and showed durable aviraemia after antiretroviral therapy was stopped. The reported effect suggests the antibody may overcome reservoir persistence by engaging T cells through a dual-receptor mechanism. The study describes a clear translational milestone: reservoir reduction plus apparent viral clearance following ART interruption, an outcome that has been difficult to reproduce with conventional approaches. The work strengthens the rationale for targeting CCR5 and CD3 simultaneously to drive immune-mediated elimination of infected cells. While the findings are preclinical and disease-specific to SIV, the model supports further evaluation of similar bispecific strategies in broader primate settings and with careful safety monitoring. For HIV cure research, the study contributes to the evidence base supporting “shock and kill” alternatives, focusing instead on immune recruitment and targeted killing at the reservoir interface.
-
Estuary Biotherapeutics raises $103M for kidney-targeted AAV gene therapy in ADPKD
Estuary Biotherapeutics launched with $103 million to develop locally delivered AAV gene therapies aimed at autosomal dominant polycystic kidney disease (ADPKD). The financing includes a $93 million Series A led by RA Capital Management plus a $10 million seed round co-led by 4BIO Capital and GV. The company says it will advance two lead programs through clinical proof-of-concept and expand its kidney-targeting platform. Both therapies are intended to restore polycystin levels across the nephron by delivering gene therapies that address the genes behind more than 90% of ADPKD cases. Estuary positions the approach as differentiated from currently approved disease-modifying care, citing that Otsuka’s tolvaptan slows progression without correcting the underlying cause. Its strategy targets delivery as the central barrier to effective gene therapy in inherited kidney disease. If successful, the company’s platform could reshape how locally administered AAV treatments are designed for organ-specific gene replacement, particularly for nephron-level distribution challenges.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.